{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T17:15:09Z","timestamp":1732036509636},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2014ZX09507008"],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2013KYA181"],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["51375444","81301293"],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.compbiolchem.2017.01.010","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T15:00:48Z","timestamp":1486220448000},"page":"234-243","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs"],"prefix":"10.1016","volume":"67","author":[{"given":"Xiaolong","family":"Jia","sequence":"first","affiliation":[]},{"given":"Yiyang","family":"Li","sequence":"additional","affiliation":[]},{"given":"Alok","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Yulong","family":"Li","sequence":"additional","affiliation":[]},{"given":"Guohai","family":"Xie","sequence":"additional","affiliation":[]},{"given":"Guoyao","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Junhui","family":"Jiang","sequence":"additional","affiliation":[]},{"given":"Yue","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Xianting","family":"Ding","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0005","first-page":"2281","article-title":"Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity","volume":"7","author":"Ding","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0010","doi-asserted-by":"crossref","first-page":"065003","DOI":"10.1088\/1478-3975\/11\/6\/065003","article-title":"Discovery of a low order drug-cell response surface for applications in personalized medicine","volume":"11","author":"Ding","year":"2014","journal-title":"Phys. Biol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0000000000000222","article-title":"Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer","author":"Ding","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0020","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2121-7-6","article-title":"Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study","volume":"7","author":"Fabbri","year":"2006","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0030","first-page":"1","article-title":"Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons","author":"Felix","year":"2016","journal-title":"Nat. Publ. Gr."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clgc.2013.04.007","article-title":"Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: A pharmacogenetic assessment of outcome and toxicity","volume":"11","author":"Figg","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0040","unstructured":"Honda, Y., Ding, X., Mussano, F., Wiberg, A., Ho, C., Nishimura, I., 2013. and human mesenchymal stem cells 1\u20139. 10.1038\/srep03420"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00726-009-0394-9","article-title":"Positron emission tomography imaging of prostate cancer","volume":"39","author":"Hong","year":"2010","journal-title":"Amino Acids"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0050","article-title":"Application of fractional factorial designs to study drug combinations","volume":"30","author":"Jaynes","year":"2013","journal-title":"Stat. Med."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/sim.6882","article-title":"Using blocked fractional factorial designs to construct discrete choice experiments for healthcare studies","author":"Jaynes","year":"2016","journal-title":"Stat. Med"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0060","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/qre.1900","article-title":"Use of orthogonal array composite designs to study lipid accumulation in a cell-Free system","volume":"32","author":"Jaynes","year":"2016","journal-title":"Qual. Reliab. Eng. Int."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0065","first-page":"481","article-title":"Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients: experience in a single institute","volume":"57","author":"Kinebuchi","year":"2011","journal-title":"Acta Urol. Jpn."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/240642","article-title":"Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers","volume":"2014","author":"Lamberti","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0075","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.breast.2009.05.004","article-title":"Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet)","volume":"18","author":"Leonard","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0080","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CAD.0000000000000365","article-title":"Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo","author":"Li","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0085","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4155\/bio.11.158","article-title":"Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge","volume":"3","author":"Lindegardh","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0090","unstructured":"Miller, R.E., Sweeney, C.J., 2016. Chemotherapy for metastatic castrate-sensitive prostate cancer 1\u20136. 10.1038\/pcan.2016.10"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0095","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.canlet.2008.09.023","article-title":"Transferrin receptor-dependent cytotoxicity of artemisinin \u2013 transferrin conjugates on prostate cancer cells and induction of apoptosis","volume":"274","author":"Nakase","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nprot.2016.017","article-title":"Optimization of drug combinations using feedback system control","volume":"11","author":"Nowak-sliwinska","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0105","first-page":"14","article-title":"Docetaxel for the treatment of hormone-refractory prostate","volume":"5","author":"Petrylak","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.purol.2009.04.010","article-title":"Characteristics of prostate cancer in men less than 50-year-old","volume":"19","author":"Peyromaure","year":"2009","journal-title":"Prog. Urol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0115","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/jm0303711","article-title":"Anticancer and antimalarial efficacy and safety of artemisinin-Derived trioxane dimers in rodents","volume":"47","author":"Posner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.breast.2006.06.008","article-title":"Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the gepartrio trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response","volume":"16","author":"Rody","year":"2007","journal-title":"Breast"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0125","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0130","doi-asserted-by":"crossref","first-page":"18314","DOI":"10.1038\/srep18314","article-title":"Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro","volume":"5","author":"Su","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0135","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0140","doi-asserted-by":"crossref","first-page":"e011063","DOI":"10.1136\/bmjopen-2016-011063","article-title":"Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)","volume":"6","author":"Thorn","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ncomms1165","article-title":"An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells","volume":"25","author":"Tsutsui","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2105-12-386","article-title":"Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations","volume":"12","author":"Van der Borght","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0155","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1038\/srep14508","article-title":"A streamlined search technology for identification of synergistic drug combinations","volume":"5","author":"Weiss","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0160","first-page":"1","article-title":"Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38\/p53\/p21 and ATM signals","volume":"5","author":"Xie","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0165","first-page":"269","article-title":"Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration","volume":"24","author":"Xu","year":"2014","journal-title":"Stat. Sin."},{"key":"10.1016\/j.compbiolchem.2017.01.010_bib0170","first-page":"580","article-title":"Research of the effect of recombinant human endostatin and docetaxel on MMP and its following anti-neoplastic effect under different administration sequences","volume":"13","author":"Yuan","year":"2010","journal-title":"Chin. J. Lung Cancer"}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927116304571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927116304571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T01:40:08Z","timestamp":1657676408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927116304571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":34,"alternative-id":["S1476927116304571"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2017.01.010","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2017.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}